Highlights of This Issue  1

SPECIAL FEATURES

CCR 20th Anniversary Commentary

3  Clinical Cancer Research: The 20th Anniversary

CCR Translations

4  Bromodomain Inhibition in Diffuse Large B-cell Lymphoma—Giving MYC a Brake
   Anja Mottok and Randy D. Gascoyne
   See related article, p. 113

7  New, Tolerable γ-Secretase Inhibitor Takes Desmoid Down a Notch
   Dennis P. M. Hughes, Shivaani Kummar, and Alexander J. Lazar
   See related article, p. 60

CCR New Strategies

10  New Strategies in Renal Cell Carcinoma: Targeting the Genetic and Metabolic Basis of Disease
   Ramaprasad Srinivasan, Christopher J. Ricketts, Carole Sourbier, and W. Marston Linehan

Molecular Pathways

18  Molecular Pathways: Not a Simple Tube—The Many Functions of Blood Vessels
   Brent A. Orr and Charles G. Eberhart

24  Molecular Pathways: Targeting the Kinase Effectors of RHO-Family GTPases
   Tatiana Y. Prudnikova, Sonali J. Rawat, and Jonathan Chernoff

CANCER THERAPY: CLINICAL

30  Tadalafil Augments Tumor Specific Immunity in Patients with Head and Neck Squamous Cell Carcinoma

39  Tadalafil Reduces Myeloid-Derived Suppressor Cells and Regulatory T Cells and Promotes Tumor Immunity in Patients with Head and Neck Squamous Cell Carcinoma
   Donald T. Weed, Jennifer L. Vella, Isidirinha M. Reis, Adriana C. De la fuente, Carmen Gomez, Zhoukaa Sargi, Ronen Nazarian, Joseph Califano, Ivan Borrello, and Paolo Serafini

49  Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial
   Serena Di Cosimo, Siam Sathyanarayanan, Johanna C. Bendell, Andres Cervantes, Mark N. Stein, Irene Bzika, Desamparados Roda, Brian R. Haines, Theresa Zhang, Christopher G. Winter, Sharda Iha, Youyuansu, Jason Frazier, Richard A. Klinghoffer, Ann Leighton-Swayze, Yang Song, Scot Ebbinghaus, and Jose Baselga

60  A Phase I, Dose-Finding Study in Patients with Advanced Solid Malignancies of the Oral γ-Secretase Inhibitor PF-03084014
   See related commentary, p. 7

68  A Phase I Study of Veliparib (ABT-888) in Combination with Low-Dose Fractionated Whole Abdominal Radiation Therapy in Patients with Advanced Solid Malignancies and Peritoneal Carcinomatosis
   Kim A. Reiss, Joseph M. Herman, Marianna Zahurak, Anthony Bade, Laura A. Dawson, Angela Scardina, Caitlin Joffe, Emily Petito, Amy Hacker-Prietz, Robert J. Kinders, Liouwa Wang, Alice Chen, Sarah Temkin, Naomi Horiba, Lillian L. Siu, and Nilofar A. Azad

77  First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan-Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors
   Debashis Sarker, Joo Eun Ang, Richard Baird, Rebecca Kistenle, Kruna Shah, Victor Moreno, Paul A. Clarke, Florence J. Raynaud, Gallia Levy, Joseph A. Ware, Kayllyn Mazin, Ray Lin, Jenny Wu, Jill Fredrickson, Jill M. Spoorke, Mark R. Lackner, Yibing Yan, Lori S. Friedman, Stan B. Kaye, Mika K. Derynck, Paul Workman, and Johann S. de Bono
First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors
Geoffrey I. Shapiro, Eunice Kwak, Bruce J. Dezube, Murray Yule, John Ayrton, John Lyons, and Danuka Mahadevan

PERSONALIZED MEDICINE AND IMAGING
Preexisting MEK1P124 Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients

Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Assessment of Antiangiogenic Treatment Effects in Multiple Myeloma
Maximilian Merz, Judith Ritsch, Christina Kunz, Barbara Wagner, Sandra Sauer, Dirk Hose, Thomas Moehler, Stefan Delorme, Hartmut Goldschmidt, Christian Zechmann, and Jens Hillengass

CANCER THERAPY: PRECLINICAL
Inhibition of Bromodomain Proteins for the Treatment of Human Diffuse Large B-cell Lymphoma
Sally E. Trabucco, Rachel M. Gerstein, Andrew M. Evens, James E. Bradner, Leonard D. Shultz, Dale L. Geiser, and Hong Zhang
See related commentary, p. 4

Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1)
Hridesh Uppal, Estelle Doudevant, Kaushiki Mahapatra, Walter C. Darbonne, Daniela Bumbaca, Ben-Quan Shen, Xiaoyan Du, Ola Saad, Kristin Bowles, Steve Olsen, Gail D. Lewis Phillips, Dylan Hartley, Mark X. Slawowski, Sandhya Girish, Donna Dambach, and Vanitha Ramakrishnan

The Novel IKK2 Inhibitor LY2409881 Potently Synergizes with Histone Deacetylase Inhibitors in Preclinical Models of Lymphoma through the Downregulation of NF-κB
Changchun Deng, Mark Lipstein, Richard Rodriguez, Xavier O. Jirau Serrano, Christine McIntosh, Wei-Yann Tsai, Andrew S. Wasmuth, Susan Jaken, and Owen A. O’Connor

CD99 Triggering in Ewing Sarcoma Delivers a Lethal Signal through p53 Pathway Reactivation and Cooperates with Doxorubicin
Clara Guerzonni, Valentina Fiori, Mario Terracciano, Maria Cristina Manara, Diego Moricoli, Michela Pasello, Marika Scialdone, Giordano Nicoletti, Mara Gellini, Sabrina Dominici, Claudia Chiodoni, Pier Maria Fornasar, Pier-Luigi Lollini, Mario P. Colombo, Piero Pici, Maurizio Cianfriqglia, Mauro Magnani, and Katia Scoltandi

Low Expression of the E3 Ubiquitin Ligase CBL Confers Chemoresistance in Human Pancreatic Cancer and Is Targeted by Epidermal Growth Factor Receptor Inhibition
Brian E. Kadera, Paul A. Toste, Nanping Wu, Luyi Li, Andrew H. Nguyen, David W. Dawson, and Timothy R. Donahue

Cabozaantinib Overcomes Crizotinib Resistance in ROS1 Fusion-Positive Cancer
Ryohei Katayama, Yuka Kobayashi, Luc Friboulet, Elizabeth L. Lockerman, Sumie Koike, Alice T. Shaw, Jeffrey A. Engelman, and Naoya Fujita

Development of a Prognostic Genetic Signature to Predict the Metastatic Risk Associated with Cutaneous Melanoma

Molecular Characterization of Choroid Plexus Tumors Reveals Novel Clinically Relevant Subgroups
Diana M. Merino, Adam Shlien, Anita Villani, Malgorzata Pienkowska, Stephen Mack, Vijay Ramaswamy, David Shih, Ruth Tavetossian, Ana Novokmet, Sanah Choufani, Rina Dvir, Myran Ben-Arush, Brent T. Harris, Eugene I. Hwang, Rishi Lulla, Stefan M. Pfister, Maria Isabel Achatz, Nada Jabado, Jonathan L. Finlay, Rosanna Weksberg, Cynthia Hawkins, Michael D. Taylor, Uri Tabori, David W. Ellison, Richard J. Gilbertson, and David Malkin
The Ability of Bilirubin in Identifying Smokers with Higher Risk of Lung Cancer: A Large Cohort Study in Conjunction with Global Metabolomic Profiling
Chi-Pang Wen, Fanmao Zhang, Dong Liang, Christopher Wen, Jian Gu, Heath Skinner, Wong-Ho Chow, Yuanqing Ye, Xia Pu, Michelle A.T. Hildebrandt, Maosheng Huang, Chien-Hua Chen, Chao Agnes Hsiung, Min Kuang Tsai, Chwen Keng Tsao, Scott M. Lippman, and Xifeng Wu

Activation of IL6/IGFIR Confers Poor Prognosis of HBV-Related Hepatocellular Carcinoma through Induction of OCT4/NANOG Expression
Te-Sheng Chang, Yu-Chih Wu, Ching-Chi Chi, Wei-Chi Su, Pey-Jium Chang, Kam-Fai Lee, Tao-Hsin Tung, Jui Wang, Jun-Jen Liu, Shui-Yi Tung, Liang-Mou Kuo, Hong-Nerng Ho, Thai-Yen Ling, and Yen-Hua Huang

Effects of BRCA1- and BRCA2-Related Mutations on Ovarian and Breast Cancer Survival: A Meta-analysis
Qian Zhong, Hong-Ling Peng, Xia Zhao, Lin Zhang, and Wei-Ting Hwang

LETTERS TO THE EDITOR

Diffusion-Weighted MRI for Lymphoma Staging—Letter
Hugo J.A. Adams and Thomas C. Kwee

Diffusion-Weighted MRI for Lymphoma Staging—Response
Marius E. Mayerhoefer and Markus Raderer

ABOUT THE COVER

The cover shows the results of an unsupervised two-dimensional hierarchical clustering analysis of the 5,000 most variable genes classifying breast tumors into ER\(^+\), HER2\(^+\), or triple-negative (ER\(^-\), PR\(^-\), HER2\(^-\)) subtypes. The analysis was performed on 800 breast tumors obtained from the Karolinska Institutet, Sweden. The RAS gene expression signature was high in the triple-negative subtype and low in the ER\(^+\) subtype. For details, see the article by Di Cosimo and colleagues on page 49 of this issue.